Compounds and methods for inhibiting fascin

1. A compound of Formula II

or tautomer thereof, and/or a pharmaceutically acceptable salt thereof;

wherein

R 1 is phenyl, 5-membered heteroaryl or 6-membered heteroaryl, wherein the phenyl, 5-membered heteroaryl or 6-membered heteroaryl is optionally substituted with 1 to 3 R 6 ;

L 2 is selected from the group consisting of —C(O)NH—, —NHC(O)—, —C(O)CH 2 —, —CH 2 C(O)—, —NHCH 2 —, and —CH 2 NH—;

R 2 is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; wherein the 6- to 10-membered aryl or 5- to 10-membered heteroaryl is optionally substituted with 1 to 4 R 4 , wherein each R 4 is independently selected from the group consisting of lower alkyl, lower haloalkyl, phenyl (optionally substituted with lower alkyl, halo or lower haloalkyl, or —OH), —OH, —OR 7 , —SH, —SR 7 , —NR 10 R 10 , halo, cyano, nitro, —COH, —COR 7 , —CO 2 H, —CO 2 R 7 , —CONR 10 R 10 , —OCOR 7 , —OCO 2 R 7 , —OCOR 10 R 10 , —NR 10 COR 7 , —NR 10 CO 2 R 7 , —SOR 7 , —SO 2 R 7 , —SO 2 NR 10 R 10 , and —NR 10 SO 2 R 7 ;

each R 3 is independently selected from the group consisting of lower alkyl, lower haloalkyl, —OH, —OR 7 , —SH, —SR 7 , —NR 10 R 10 , halo, cyano, nitro, —COH, —COR 7 , —CO 2 H, —CO 2 R 7 , —CONR 10 R 10 , —OCOR 7 , —OCO 2 R 7 , —OCONR 10 R 10 , —NR 10 COR 10 , —NR 10 CO 2 R 10 , —SOR 7 , —SO 2 R 7 , —SO 2 NR 10 R 10 , and —NR 10 SO 2 R 7 ;

m is 0, 1, 2 or 3;

each R 6 is independently selected from the group consisting of halo, cyano, lower alkyl and lower haloalkyl;

R 7 is lower alkyl or lower haloalkyl; and

each R 10 is independently hydrogen or lower alkyl, or two R 10 together with the atom(s) attached thereto form a 4- to 6-membered ring;

provided that the compound is not N-(1-(4-(trifluoromethyl)benzyl)-1H-indazol-3-yl)furan-2-carboxamide,

wherein one or more hydrogen is replaced by a deuterium.

2. The compound of claim 1 , wherein R 1 is phenyl optionally substituted with 1 to 3 R 6 .

3. The compound of claim 1 , wherein L 2 is selected from the group consisting of —C(O)NH— and —NHC(O)—.

4. The compound of claim 1 , wherein R 2 is the 5- to 10-membered heteroaryl.

5. The compound of claim 1 , wherein m is 1, 2, or 3.

6. The compound of claim 1 , wherein R 2 is optionally substituted with 1 to 4 R 4 , and R 2 is selected from the group consisting of furan, benzofuran, pyridine, pyridazine, pyrimidine, pyrazine, thiophene, thiazole, isothiazole, oxazole, isoxazole, oxadiazole, imidazole, pyrrole, and pyrazole.

7. The compound of claim 1 , wherein R 4 is not optional and is selected from the group consisting of lower alkyl, halo, lower haloalkyl, —OH, —OR 7 , cyano and phenyl optionally substituted methyl, and wherein R 7 is lower alkyl or lower haloalkyl.

8. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

9. The compound of claim 1 , wherein R 2 is selected from the group consisting of